Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system, European Medicines Agency, Amsterdam, the Netherlands, from 12 October 2026 to 16 October 2026

Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system, European Medicines Agency, Amsterdam, the Netherlands, from 9 November 2026 to 13 November 2026

Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system, European Medicines Agency, Amsterdam, the Netherlands, from 7 December 2026 to 11 December 2026

Human medicines European public assessment report (EPAR): Iloperidone Vanda Pharmaceuticals, iloperidone, Status: Opinion

HMPC meeting report on European Union herbal monographs, guidelines and other activities - 4-6 May 2026

Human medicines European public assessment report (EPAR): Dazparda, insulin aspart, Date of authorisation: 27/04/2026, Status: Authorised

EU tracks progress towards 2030 clinical trial targets

Clinical trials in human medicines

Human medicines European public assessment report (EPAR): Cerdelga, eliglustat, Date of authorisation: 19/01/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Arava, leflunomide, Date of authorisation: 02/09/1999, Revision: 45, Status: Authorised